In Antiangiogenic Agents in Cancer Therapy, Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy.
Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished, where the experimental therapeutics of antiangiogenic agents are going, and the continuing evolution of their role in cancer treatment and novel drug development. Comprehensive and up-to-date, this book constitutes a key resource-rich in novel means and methods-for the clinical development of this important, highly promising new class of anticancer drugs.

Klappentext

Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished , where the experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of their role in cancer treatment and novel drug development.

Inhalt

Part I. Antiangiogenic Factors and Tumor Vasculature. Angiogenesis and Blood Flow in the Solid Tumors, Zishan Haroon, Kevin G. Peters, Charles S. Greenberg, and Mark W. Dewhirst. Oxygenation of Solid Tumors in Animals and Patients, Eric Lartigau and Marcelle Guichard. Role of Inflammatory Mediators in Angiogenesis, Federico Bussolino and Alberto Mantovani. Intra- and Extracellular pH in Solid Tumors, Chang W. Song, HeonJoo Park, and Brian D. Ross. Contribution of the Extracellular Matrix and Macrophages in Angiogenesis, Peter J. Polverini. Regulation of Angiogenesis by the Organ Microenvironment, Diane R. Bielenberg and Isaiah J. Fidler. Fibroblast Growth Factors in Tumor Progression and Angiogenesis, Israel Vlodavsky and Gerhard Christofori. Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis, Napoleone Ferrara. Regulatory Aspects of Neovascularization: Regulation of Wound Angiogenesis by Metabolic Alterations M. Zamirul Hussain, Q. Perveen Ghani, John J. Feng, and Thomas K. Hunt. Part II. Antiangiogenic Agents. Squalamine: A New Angiostatic Steroid, Jon I. Williams. Cartilage as a Source of Natural Inhibitors of Angiogenesis, Vincent Castronovo, Violetta Dimitriadou, Pierre Savard, Marc Rivière, and Eric Dupont. Thrombospondin as an Inhibitor of Angiogenesis, David W. Dawson and Noël P. Bouk. Matrix Metalloproteinase Inhibitors, Peter D. Brown and Mark Whittaker. Angiostatin and Other Plasminogen Fragments, B. Kim Lee Sim. Dietary and Nutritional Modulation of Tumor Angiogenesis, Purna Mukherjee, Jin-Rong Zhou, Alexander V. Sotnikov, and Steven K. Clinton. Thalidomide and Analogs,Taturo Udagawa, Henk M. W. Verheul, and Robert J. D'Amato. Part III. In Vivo Studies and Clinical Trials. Potentiation of Cytotoxic Cancer Therapies by Antiangiogenic Agents, Beverly A. Teicher. Prognostic Significance of Tumor Vascularity, Gianpietro Gasparini and Adrian L. Harris. Endpoints for Determination of Efficacy of Antiangiogenic Agents in ClinicalTrials, William J. Gradishar. Retinoids and Interferons as Antiangiogenic Cancer Drugs, John L. Clifford, Joseph M. Miano, and Scott M. Lippman. Pentosan Polysulfate: A Polysaccharide That Inhibits Angiogenesis by Binding Growth Factors, William D. Figg, James M. Pluda, and Oliver Sartor. TNP-470, Deborah M. Milkowski and Rachelle A. Weiss. Batmastat and Marmastat in Cancer: Summary of Early Clinical Data, Henrik S. Rasmussen. Thalidomide: A Prodrug That Inhibits Angiogenesis, William D. Figg, Eddie Reed, Shawn Green, and James M. Pluda.